Efficacy of rituximab-containing regimens on post-transplantation lymphoproliferative disorder following haploidentical hematopoietic stem cell transplantation: a report of 3 cases

VernacularTitle:常规方案联合利妥昔单抗治疗单倍体相合HSCT后淋巴细胞增生性疾病三例
Author: Mei XUE ; Zhidong WANG ; Jing LIU ; Ling ZHU ; Dongmei HAN ; Xiaoli ZHENG ; Li DING ; Hongmin YAN ; Hengxiang WANG
Publication Type:Journal Article
Keywords: Hematopoietic stem cell transplantation; Lymphoproliferative disorder; Rituximab
From: Chinese Journal of Organ Transplantation 2011;32(8):488-491
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy of rituximab-containing regimens on post-transplantation lymphoproliferative disorder (PTLD) following haploidentical hematopoietic stem cell transplantation (HSCT). Methods The clinical data of 3 cases of PTLD after haploidentical HSCT were analyzed retrospectively. Time to development of PTLD ranged from 57 to 164 days after HSCT.The main symptoms included fever, superficial lymph node enlargement. Epstein-Bart virus (EBV)-positive B-cell PTLD was diagnosed by biopsy of lymph node. Management of 3 patients consisted of withdraw of immunosuppressive treatment, anti-viral therapy, rituximab (375 rng/m2 , per week for four weeks) monotherapy or chemotherapy plus rituximab. Results All the patients had complete remission after treatment. Conclusion PTLD is a serious complication of HSCT especially haploidentical HSCT. Rituximab-containing regimens are potentially effective, well-tolerated with mild toxicity and improve the prognosis of PTLD following haploidentical HSCT.